Inhiplat Tablets (Clopidogrel Camisilate)

Adult dose

○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start with a loading dose of 300 mg of this drug once daily on the day treatment is initiated, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ～ 325 mg must be administered concomitantly with this drug once daily. 3. For patients with atrial fibrillation, administer 75 mg of this drug orally once daily. Aspirin 75 ～ 100 mg must be administered concomitantly with this drug once daily. ○ Patients with renal impairment : Treatment experience in patients with renal impairment is limited. ○ Patients with hepatic impairment : Treatment experience in patients with moderate hepatic disease and a bleeding diathesis is limited. This drug may be administered with or without food.

This medication prevents blood platelets from aggregating and thereby preventing blood clot formation. People with genetically reduced function of the CYP2C19 enzyme may experience reduced efficacy of this medication; thus, alternative treatment methods should be considered in such cases. Individuals who are allergic to this medication or its ingredients, patients with bleeding conditions, patients with severe liver damage, nursing women, and those with certain genetic disorders should not take this medication. Patients at risk of bleeding should use this medication cautiously and report any bleeding symptoms immediately to their doctor. Especially, if surgery is planned, the medication should be discontinued 5 to 7 days before the procedure, and caution is warranted when using it with other drugs that increase the risk of bleeding. During long-term use of this medication, regular blood tests to check for bleeding should be performed. This medication may cause various side effects, including gastrointestinal disturbances, headaches, dizziness, rashes, etc.; if severe bleeding or blood-related abnormal symptoms occur, seek medical attention immediately. It is advisable not to take this medication during pregnancy unless in special cases, and nursing women should consult a physician before use. Safety and efficacy in children have not been established. Elderly patients are at higher risk of bleeding; therefore, dosage adjustments and monitoring of their condition are necessary. This medication can interact with other drugs, so inform your doctor or pharmacist of any other medications being taken. An overdose may carry a risk of bleeding, so adhere to the prescribed dosage and consult medical personnel immediately if any unusual symptoms arise. This medication should be kept out of the reach of children, and it is advisable not to transfer it to other containers.

• Hemorrhage
• gastrointestinal hemorrhage
• hemorrhage requiring hospitalization
• purpura
• contusion
• hematoma
• nasal bleeding
• hematuria
• intraocular hemorrhage
• intracranial hemorrhage

This medication may be sensitive to air and moisture, so it must be stored in a tightly closed container. The storage temperature should be maintained between 1 to 30 degrees Celsius at room temperature. This will help preserve the effectiveness of the medication for a longer duration.

Appearance

Pink round film-coated tablets

Package unit

30 tablets (10 tablets/ Alu-Alu x 3)